Topical application of prostaglandin hypotensive agents
Patent 4254145 Issued on March 3, 1981. Estimated Expiration Date: 
August 16, 1998. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
August 16, 1998. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 3551554 15-Deoxy-16-hydroxy-16-vinyl and cyclopropyl substituted prostanoic acids and congeners Novel prostanoic acids Phenacyl-type esters of PGA1 and PGA2 Oxaprostaglandins Treatment of peripheral vascular disease by non-intraarterial administration of prostaglandin E1 Patent #: 4103026 InventorAssigneeApplicationNo. 05/934199 filed on 08/16/1978US Classes:514/530, Z contains a cyclopentyl or cyclopentene ring514/573, Cyclopentyl or cyclopentene (e.g., prostaglandins, etc.)514/690Alicyclic ring containingExaminersPrimary: Schenkman, LeonardAttorney, Agent or FirmInternational ClassesA61K 47/18 (20060101)A61K 47/16 (20060101) A61K 31/557 (20060101) AbstractPharmaceutical compositions useful as vasodilators whose activity may be restricted to the site of application by control of the dose applied which comprises a prostaglandin selected from the group consisting of the natural and synthetic analogs of the PGE, PGA and PGEଲ types in a pharmaceutical carrier. The compositions are applied topically and by local injection to increase peripheral circulation, or to treat peripheral vascular disorders of the arteriospastic and occlusive types. The prostaglandins and pharmaceutical compositions containing them disclosed herein are also administered topically and by local injection to lower the systemic blood pressure of man and warm blooded animals. Systemic action is obtained by the use of an effective dosage greater than that used to induce localized action at the site of application.Other References
| |
